BN-104

N/A

Report date: 2023/10/25 11:38:07
NME

Base Information

Drug NameBN-104
Drug Alias NameBN-104BN104BNM-1192
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMenin inhibitors
TargetsMenin
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBionova Pharmaceuticals (Shanghai) Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInstitut De Recherches Internationales Servier Iris SarlBionova Pharmaceuticals (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A